It’s important for the pharma industry to take a closer look at the benefits of going beyond the pill and leveraging technology to deliver better care resulting in better patient outcomes and potential savings to the overall health system.
Artificial intelligence generated plenty of chatter amongst the pharma marketing intelligentsia in 2018. Will 2019 be the year when the industry fully embraces it as more than just a tactic?
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
Leadership representing the 2018 Manny Award agency and network winners and finalists share their views on various healthcare industry trends and developments.
The top pharmaceutical companies are trying to proactively tackle, through shifts in R&D strategy and other tactics, the healthcare demands of the future.
There were as many billion-dollar brands in 2017 as there have been in any other calendar year despite the cratering effects of massive patent cliffs in 2012 and 2015.
Current health systems built to evaluate and pay for traditional drugs are going to struggle with gene and other unusual therapies – but manufacturers can take steps before launch to define how manufacturers assess and value these new products.
This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.
A recent study of DTC advertising appearing in the Journal of General Internal Medicine concluded that few broadcast ads are compliant with FDA’s guidelines. The reality, though, might not be so cut and dried.
As more innovative – yet even more expensive – therapies enter the U.S. market, brand marketers will have to find equally new and innovative ways to prove the value of their medicines to payers and patients, especially as insurance plans continue to put more of the cost burden on patients.
On Oct. 28, 2016, my mother, Joan Biamonte, died of complications from metastatic carcinoma of the lung. Despite having her original tumor characterized and going through a regimen of chemotherapy allegedly tailored to her tumor type, her cancer proliferated and spread into her liver and brain.
The internal watchdog at the U.S. Department of Health and Human Services warned the office tasked with administering federal health insurance programs that Mylan NV’s EpiPen was improperly classified as a generic drug in 2009, Senator Charles Grassley said.
Privately held drugmaker Kaleo Inc. announced plans for a U.S. relaunch of its Auvi-Q injector for life-threatening allergic reactions in the first half of 2017.
Britain’s healthcare cost agency NICE plans to fast-track its recommendations for the most cost-effective new drugs.
Nearly three-quarters of U.S. dermatologists received payments worth a collective $34 million from drug companies in 2014, according to a new analysis of a public database.
Robert Mulroy, CEO of Merrimack Pharmaceuticals, has resigned his position as part of a corporate restructuring move that will result in a 22 percent workforce reduction.
Regeneron Pharmaceuticals’ combo therapy containing its flagship eye drug, Eylea, was inferior to Eylea alone in a mid-stage trial involving patients with wet AMD.
Amgen’s multiple myeloma drug did not fare better than Takeda’s older therapy Velcade in a study involving patients who had not yet been treated for the disease.
Johnson & Johnson said the U.S. Food and Drug Administration approved the company’s blockbuster psoriasis drug Stelara for adults with Crohn’s disease.